Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs

MeSH terms

• Adolescent
• Adult
• Child
• Child, Preschool
• Female
• Follow-Up Studies
• Humans
• Imidazoles* / administration & dosage
• Imidazoles* / adverse effects
• Infant
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
• Male
• Protein Kinase Inhibitors* / administration & dosage
• Protein Kinase Inhibitors* / adverse effects
• Pyridazines* / administration & dosage
• Pyridazines* / adverse effects